arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Emergent BioSolutions Inc.

EBS
$5.85 ▼ -0.05 (-0.85%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Fair
Bearish
auto_awesome

Analytical Summary

Emergent BioSolutions Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $300.1M
Dividend Yield —
Revenue Growth -52.4% ↘
Op. Margin -33.9% ↗
ROIC -4.0% ↗
FCF / Share $1.89 ↗
Trailing P/E —
Price / Book 1.0x
FCF Yield 32.3%
Debt / Equity 1.64
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$110.00M
↓ -52.4% —
Net Income Profit after all expenses
$6.80M
↓ -90.0% —
Operating Margin Operating profit as % of sales
-33.9%
↑ +36.5% 64th
FCF / Share Free cash flow per share
$1.89
↑ +80.3% —
Long-Term Debt Long-term obligations
$514.30M
↓ -12.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↓
68
Returns ↓
68
Financial Health →
43
Cash Quality ↑
92

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 69 quarters